Looking at iBio, Inc.’s (IBIO) past performance, we will examine different stock moving trends. This stock rose 26.96% in the last month and 1.39% last week. The stock has decreased -73.06% within the last six months, with a year-over-year gain of 403.45%. Today, the year-to-date (YTD) performance of this stock stands at 39.05%.
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
What is the exact trade of iBio?
When it comes to discovering hidden gems within the stock market, Stock Wire News has consistently provided invaluable insights. Stock Wire News invites you to explore their upcoming Wealth Building Report. This report will shine a spotlight on little-known companies with the potential for substantial growth in 2024, and it's completely FREE for a limited time.
Claim the free report now by clicking here and start discovering the hidden gems of the market
Sponsored
The iBio Group is a world leader in the manufacture of plant-based biologics. A combination of vertical farming, automated hydroponics, and glycan engineering technologies enables the company’sFastPharming System to quickly deliver high-quality monoclonal antibodies, vaccines, bio-inks, and other proteins. The FastPharming Platform enables iBio to develop proprietary products, including therapeutics for infectious and fibrotic diseases, among others.
Read More
- 3 Best Gene Therapy Stocks for long-term Investment
- Two of the Best Pharmaceutical Stocks to Watch for in 2021
In the after-hours session, shares of iBio, Inc. (IBIO) rose. The IBIO stock rose over 15% during the extended period to $1.68. Even though there has been no news from the company, momentum has been building since last month after several reports from the company.
Most Recent Developments
On December 28, 2020, Martin Brenner, DVM, Ph.D. has been appointed Chief Scientific Officer of iBio, Inc., (IBIO), effective January 18, 2020.
On December 11, 2020, In addition to the gross proceeds of $35.0 million for the underwritten offering, iBio announced that it closed its private placement offering of 29.7 million shares of common stock for $35 to $40 per share. The underwriter also has the right to purchase an additional 4.4 million shares from iBio within 30 days.
On December 8, 2020, iBio, Inc. (IBIO) announced the pricing of its underwritten public offering of approximately 29.7 million shares of its common stock. The offering is expected to generate gross proceeds of $35.0 million, including all underwriter discounts and commissions. Under usual closing conditions, the offering should close on or about December 10, 2020.
Insider Ownership of IBIO stock
a number of high-value investors own iBio Inc. (iBio). Its largest direct holder is Blackrock Inc., with 5448105 shares. The second-largest direct holder is Vanguard Group, Inc. (The), with 2675662 shares of its stock. In third place with 1498346 shares of iBio is Geode Capital Management, LLC.
Get the hottest stocks to trade every day before the market opens 100% free. Click here now.
Finally, In the Eye of Analysts
The analysts are predicting that the iBio stock price might increase by 27.0%. A high price target price of $2.00 was set for the shares to achieve in the next 12 months. Analysts also expect traders to keep the stock price between $2.00 and $2.50. The stock’s current price will increase by 27.0% if that happens. So far this year, the price of iBiohas risen by 39.05%.